This is a Phase I, open-label dose finding study to assess the safety, tolerability,
manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with
metastatic castrate-resistant prostate cancer (mCRPC). Up to 4 total dose levels will be
evaluated using a 3+3 dose escalation design.